These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 22560128)

  • 1. Oral β-blockade in relation to energy expenditure in clinically stable patients with liver cirrhosis: a double-blind randomized cross-over trial.
    Lee WG; McCall JL; Gane EJ; Murphy R; Plank LD
    Metabolism; 2012 Nov; 61(11):1547-53. PubMed ID: 22560128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypermetabolism predicts reduced transplant-free survival independent of MELD and Child-Pugh scores in liver cirrhosis.
    Mathur S; Peng S; Gane EJ; McCall JL; Plank LD
    Nutrition; 2007 May; 23(5):398-403. PubMed ID: 17395427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nadolol reduces insulin sensitivity in liver cirrhosis: a randomized double-blind crossover trial.
    Lee WG; Murphy R; McCall JL; Gane EJ; Soop M; Tura A; Plank LD
    Diabetes Metab Res Rev; 2017 Mar; 33(3):. PubMed ID: 27667324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resting energy expenditure should be measured in patients with cirrhosis, not predicted.
    Madden AM; Morgan MY
    Hepatology; 1999 Sep; 30(3):655-64. PubMed ID: 10462371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nadolol plus spironolactone in the prophylaxis of first variceal bleed in nonascitic cirrhotic patients: A preliminary study.
    Abecasis R; Kravetz D; Fassio E; Ameigeiras B; Garcia D; Isla R; Landeira G; Dominguez N; Romero G; Argonz J; Terg R
    Hepatology; 2003 Feb; 37(2):359-65. PubMed ID: 12540786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Octreotide compared with placebo in a treatment strategy for early rebleeding in cirrhosis. A double blind, randomized pragmatic trial.
    D'Amico G; Politi F; Morabito A; D'Antoni A; Guerrera D; Giannuoli G; Traina M; Vizzini G; Pasta L; Pagliaro L
    Hepatology; 1998 Nov; 28(5):1206-14. PubMed ID: 9794903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of measured and predicted energy expenditure in patients with liver cirrhosis.
    Teramoto A; Yamanaka-Okumura H; Urano E; Nakamura-Kutsuzawa T; Sugihara K; Katayama T; Miyake H; Imura S; Utsunomiya T; Shimada M; Takeda E
    Asia Pac J Clin Nutr; 2014; 23(2):197-204. PubMed ID: 24901087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Catecholamines and heart function in heart transplant patients: effects of beta1- versus nonselective beta-blockade.
    Leenen FH; Davies RA; Fourney A
    Clin Pharmacol Ther; 1998 Nov; 64(5):522-35. PubMed ID: 9834044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Energy metabolism in patients with severe chronic viral hepatitis].
    Meng QH; Yu HW; Feng YM; Li XM; Yu SQ; Li YX; Ni MM; Wang JH; Wang H; Liu Y
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(42):2982-5. PubMed ID: 18261330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accurate determination of energy needs in hospitalized patients.
    Boullata J; Williams J; Cottrell F; Hudson L; Compher C
    J Am Diet Assoc; 2007 Mar; 107(3):393-401. PubMed ID: 17324656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of chronic beta-blockade on QT interval in patients with liver cirrhosis.
    Zambruni A; Trevisani F; Di Micoli A; Savelli F; Berzigotti A; Bracci E; Caraceni P; Domenicali M; Felline P; Zoli M; Bernardi M
    J Hepatol; 2008 Mar; 48(3):415-21. PubMed ID: 18194821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: results of a pilot randomized controlled clinical trial.
    Conchillo M; de Knegt RJ; Payeras M; Quiroga J; Sangro B; Herrero JI; Castilla-Cortazar I; Frystyk J; Flyvbjerg A; Yoshizawa C; Jansen PL; Scharschmidt B; Prieto J
    J Hepatol; 2005 Oct; 43(4):630-6. PubMed ID: 16024131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased resting energy expenditure in hemodialysis patients with severe hyperparathyroidism.
    Cuppari L; de Carvalho AB; Avesani CM; Kamimura MA; Dos Santos Lobão RR; Draibe SA
    J Am Soc Nephrol; 2004 Nov; 15(11):2933-9. PubMed ID: 15504947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypermetabolism in clinically stable patients with liver cirrhosis.
    Müller MJ; Böttcher J; Selberg O; Weselmann S; Böker KH; Schwarze M; von zur Mühlen A; Manns MP
    Am J Clin Nutr; 1999 Jun; 69(6):1194-201. PubMed ID: 10357739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daily energy and substrate metabolism in patients with cirrhosis.
    Greco AV; Mingrone G; Benedetti G; Capristo E; Tataranni PA; Gasbarrini G
    Hepatology; 1998 Feb; 27(2):346-50. PubMed ID: 9462629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Caffeine-herbal ephedra combination increases resting energy expenditure, heart rate and blood pressure.
    Vukovich MD; Schoorman R; Heilman C; Jacob P; Benowitz NL
    Clin Exp Pharmacol Physiol; 2005; 32(1-2):47-53. PubMed ID: 15730434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship of resting energy expenditure with liver function and nutritional status in patients with alcoholic cirrhosis.
    Pierrugues R; Blanc P; Daures JP; Michel H
    Nutrition; 1992; 8(1):22-5. PubMed ID: 1562784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Timing protein intake increases energy expenditure 24 h after resistance training.
    Hackney KJ; Bruenger AJ; Lemmer JT
    Med Sci Sports Exerc; 2010 May; 42(5):998-1003. PubMed ID: 19997003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of hydrophilic and lipophilic beta-blockers on heart rate, ventricular repolarization and their interrelationship in normal subjects.
    Iacoviello M; Massari F; De Laura D; Guida P; Mastropasqua F; Forleo C; Rizzon P; Pitzalis MV
    Ital Heart J; 2000 May; 1(5):331-5. PubMed ID: 10832808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. Franco-Italian Multicenter Study Group.
    Poynard T; Calès P; Pasta L; Ideo G; Pascal JP; Pagliaro L; Lebrec D
    N Engl J Med; 1991 May; 324(22):1532-8. PubMed ID: 1674104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.